|
Flu vaccine for the 2025-26 season is here and available to order starting today! Check out the Flu Vaccines at a Glance guide for the details on this season's products.
Initially, flu vaccine orders will be processed weekly on Tuesdays. Orders need to be in "pending state approval status" in the IIS by close of business Monday. Please allow for at least 3 days for order approval from time of submission for accountability checks. Orders will be pulled from the IIS at 8am on Tuesday and checked against the number of doses available from the CDC.
In an effort to reduce waste, the following ordering controls are in place for flu vaccine.
- Orders will be approved based on half the doses used for the same month last year
- For new providers or if no previous administration data is available, the order will be capped at 50 total doses for the order
- Every provider order is tracked and possibly reduced to stay in alignment with allocations at the start of the season
- If there is not enough vaccine in allocation, orders will be reduced based on the Vaccine Allocation Plan
Remember, orders for respiratory products do not need to be placed on your assigned ordering schedule. Orders can be placed at any time and as often as needed.
Beginning 8/27/2025, the IIS will require an inventory reconciliation submission within 14 days of a vaccine order. If the last inventory submission was not completed within the last 14 days of the date you are placing a vaccine order, the IIS will redirect you to the reconciliation page to complete an inventory reconciliation report.
Please reach out to us at WAChildhoodVaccines@doh.wa.gov with any questions.
We need your help pre-staging Nirsevimab for the coming respiratory season! If you have 50mg product of nirsevimab with an expiration date of 10/31/2025 in your inventory and will not be using it, please advertise those doses in the IIS. We will be using those advertisements to transfer doses to hospitals and larger facilities for use before expiration.
In addition, there are 100mg nirsevimab doses expiring November 30, 2025. Any provider who can not use their existing inventory before expiry, should also advertise those doses for transfer.
As a reminder, do not attempt to return or discard RSV products currently in your inventory that have not yet expired. These doses are still viable and can be used until their expiration date.
Thank you to everyone who joined us for the CVP Training Series on Ordering and Inventory Controls on August 21, 2025. For those who were unable to attend, the recording is available at the link below. Please note that viewing the recording is mandatory for all staff members involved in placing vaccine orders.
We received many insightful questions during the session. Below, you'll find a summary of the most common topics, along with our responses in the Frequently Asked Questions document.
Thank you for partnering with us to reduce vaccine waste so we can ensure the continuation of our universal purchase vaccine program.
CVP Training Series: Ordering and Inventory Control
Passcode: BG5v*Jz8
Additional tools that were shared at the training:
Training Slides including links to all the resources (PDF)
Downloadable ROQ Calculator (Excel)
Reducing Vaccine Waste Toolkit (PDF)
If you have any questions, please contact us at WAChildhoodVaccines@doh.wa.gov
Did you know that you have to manually remove your clinic's vaccine advertisement(s) in the IIS? It's true! Keeping your postings up to date is critical. Please make sure to check your listings and update as needed.
If you have transferred your advertised doses or they have expired, please make sure to update your listings.
- Click on Orders/Transfers heading in the left menus of the IIS. Then click Vaccine Advertisement to open the Vaccine Advertisement screen.
- Click on the radio button next to Advertise Vaccine for Transfer.
- Scroll down to the vaccine that was advertised and click either the Update or Delete button on the right side of the listing.
- If you need to adjust the amount of vaccine advertised click Update.
- If you need to delete the advertisement due to transfer or vaccine expiration, click Delete.
- Make sure to reconcile your inventory. Follow the instructions for How to Search, Add, Reconcile and Report Inventory.
For more on Vaccine Advertisements, please review this Quick Reference Guide for Advertising Vaccines for Transfer.
The Washington Department of Health (DOH) will host a webinar on Thursday, September 11th to discuss influenza, COVID-19 and RSV epidemiology, vaccination coverage, clinical overview, vaccine recommendations, and vaccine ordering and distribution. The webinar will be recorded and continuing education (CE) credits will be available for nurses, medical assistants, and pharmacists/pharmacy technicians. Please note that a Traino.org account is required to register for the webinar and receive CE credits.
Date: September 11, 2025
Time: 12 noon PDT
Register Here
The 2025-26 Vaccine Assessment Grid is now in effect through June 30, 2026.
As a reminder, the Grid lists vaccines and immunizations, along with their CPT codes, that are included in Childhood Vaccination Program (CVP) and for which the dosage-based assessment (DBA) process is required. This applies to healthcare providers, insurance companies, and third-party administrators (TPAs). The Grid acts like a fee schedule. Providers are required to submit the DBA with the correct Grid amount based upon date of service. Properly submitted DBAs ensure that adequate funds are available to support the state’s continued purchase of pediatric vaccines and immunizations for Washington children under age 19.
The Grid is posted to the WVA’s website in both PDF and Excel format. For more information on the billing process, please review the Provider Billing Guide. Should you have any other questions for the WVA, please contact us at info@wavaccine.org.
The updated 2025-26 influenza vaccine recommendations are expected to be published in the MMWR this week or next week. The Advisory Committee on Immunization Practices met in July and voted to recommend influenza vaccine for all persons aged 6 months and older. Single-dose formulations of influenza vaccines that are free of thimerosal as a preservative are recommended.
As RSV season starts shortly, maternal RSV vaccination with Abrysvo (Pfizer) is recommended starting in September. A single dose is recommended during pregnancy between 32 and 36 6/7 weeks’ gestation. Abrysvo is NOT recommended if the mother has received a previous RSV vaccine dose for any reason. If Abrysvo is not given or if the baby is born less than 14 days after Abrysvo is given, the infant should receive an RSV antibody for protection. Infants should receive an RSV antibody starting in October. All infants younger than 8 month whose mothers were not vaccinated with Abrysvo during pregnancy are eligible. Below are a few important points to remember as you plan for immunization of infants born this past spring and summer:
- Two antibody products are available for infants younger than 8 months: nirsevimab (Beyfortus, Sanofi) or clesrovimab (Enflonsia, Merck), given as a single dose
- Infants younger than 8 months whose mothers received Abrysvo during pregnancy or who received a dose of Beyfortus last spring should NOT be given an RSV antibody now
-
Beyfortus (and only Beyfortus) is recommended for children 8 through 19 months at increased risk for severe RSV in their second RSV season, regardless of their history of maternal vaccination or antibody administration during their first RSV season
- Clinics should send reminders and schedule infants born during the spring and summer who are due for RSV antibody in October; these infants may be missed if waiting for them to return to clinic for other reasons
- An unprotected infant who is not at high risk and turns 8 months of age is no longer eligible to receive an RSV antibody
CDC released four new resources for healthcare professionals on RSV prevention products. These materials are available on the CDC’s Respiratory Syncytial Virus (RSV) Immunizations page and include the following documents:
The American Academy of Pediatrics (AAP) recently published its own childhood immunization schedule. The biggest difference between the AAP and CDC schedules is around COVID-19 vaccination. AAP continues its support for the recommended immunization schedule for children as published by CDC in November 2024, including routine vaccination of children against COVID-19. The CDC no longer recommends routine vaccination for healthy children, although children can get vaccinated after a conversation with their doctor. In contrast, the AAP recommends all young children ages 6-23 months get vaccinated as well as children ages 2-18 years in certain risk groups. It also calls for children whose parent or guardian desires their protection from COVID-19 to have access to the vaccine.
The schedule also includes updates to recommendations on respiratory syncytial virus (RSV) and flu, and incorporates new recommendations from the past year on a pentavalent meningococcal vaccine from GSK and AAP’s recommendation to start HPV vaccination at 9-12 years.
The American College of Obstetricians and Gynecologists (ACOG) released updated clinical guidance regarding vaccination during pregnancy against COVID-19, influenza, and RSV. Here’s a summary of the recommendations:
- Patients should receive an updated COVID-19 vaccine or “booster” at any point during pregnancy, when planning to become pregnant, in the postpartum period, or when lactating. COVID-19 vaccines are effective at reducing morbidity from COVID-19 complications in pregnant patients and their infants as measured by emergency department or urgent care encounters. Data also support the benefit of vaccination in reducing pregnancy complications, such as severe maternal morbidity, preterm birth, and stillbirth.
- All individuals who are or will be pregnant during influenza season should receive an inactivated or recombinant influenza vaccine as soon as it is available, during any trimester of pregnancy. This recommendation reflects the increased risks associated with influenza infection for both pregnant patients and their newborns.
- During RSV season, patients should receive Abrysvo RSV vaccine in order to protect their infants after birth. Patients should receive the vaccine when they are between 32 0/7 and 36 6/7 weeks of gestation: 1) if they do not have a planned delivery within two weeks, 2) if they did not receive the maternal RSV vaccine during a previous pregnancy, and 3) if they are not planning to have their infant receive a monoclonal antibody, nirsevimab or clesrovimab. Patients should also understand that if they decline the maternal RSV vaccination, their infant needs a monoclonal antibody at birth.
 |
You've got mail...in the IIS! Have you ever noticed a red alert at the top of your IIS screen stating "New Messages to read"? You have a new message to read! Check it by following these steps.
- Click on View Messages under the Message heading in your left menu.
- Click on the Subject of the message to open.
- To delete a message, mark the Delete check box and then click the Delete button.
|
